Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis

BACKGROUND: In accordance with expert guidance, patients have typically continued to receive treatment with subcutaneous interferon beta-1a (sc IFN β-1a) for relapsing multiple sclerosis (MS) during the COVID-19 pandemic. METHODS: We provide a summary of outcomes among sc IFN β-1a-treated patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Freedman, Mark S., Jack, Dominic, Murgašová, Zuzana, Todorović, Milorad, Seitzinger, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479355/
https://www.ncbi.nlm.nih.gov/pubmed/34619487
http://dx.doi.org/10.1016/j.msard.2021.103283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479355/
https://www.ncbi.nlm.nih.gov/pubmed/34619487
http://dx.doi.org/10.1016/j.msard.2021.103283

Ejemplares similares